During the last session, Concert Pharmaceuticals Inc. (NASDAQ:CNCE)’s traded shares were 0.31 million, with the beta value of the company hitting 0.40. At the end of the trading day, the stock’s price was $3.95, reflecting an intraday gain of 14.49% or $0.5. The 52-week high for the CNCE share is $4.62, that puts it down -16.96 from that peak though still a striking 34.94% gain since the share price plummeted to a 52-week low of $2.57. The company’s market capitalization is $146.15M, and the average trade volume was 78.80K shares over the past three months.
Concert Pharmaceuticals Inc. (CNCE) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.80. CNCE has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.73.
Concert Pharmaceuticals Inc. (NASDAQ:CNCE) trade information
Concert Pharmaceuticals Inc. (CNCE) registered a 14.49% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 14.49% in intraday trading to $3.95 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is 23.44%, and it has moved by 21.17% in 30 days. Based on these gigs, the overall price performance for the year is 0.00%.
The consensus price target of analysts on Wall Street is $13.08, which implies an increase of 69.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9.00 and $22.00 respectively. As a result, CNCE is trading at a discount of -456.96% off the target high and -127.85% off the low.
Concert Pharmaceuticals Inc. (CNCE) estimates and forecasts
Statistics show that Concert Pharmaceuticals Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Concert Pharmaceuticals Inc. (CNCE) shares have gone down -0.88% during the last six months, with a year-to-date growth rate less than the industry average at -57.71% against 9.70. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -5.80% this quarter and then jump 13.40% in the quarter after that. In the rating firms’ projections, revenue will increase 313.40% compared to the previous financial year.
Revenue for the current quarter is expected to be $20k as predicted by 3 analyst(s). As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $7k and $5k respectively.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -0.40%. While earnings are projected to return 2.90% in 2022.
Concert Pharmaceuticals Inc. is due to release its next quarterly earnings between February 23 and February 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Concert Pharmaceuticals Inc. (NASDAQ:CNCE)’s Major holders
Concert Pharmaceuticals Inc. insiders own 3.93% of total outstanding shares while institutional holders control 62.44%, with the float percentage being 64.99%. RA Capital Management, L.P. is the largest shareholder of the company, while 78 institutions own stock in it. As of Sep 29, 2021, the company held over 3.03 million shares (or 8.75% of all shares), a total value of $9.92 million in shares.
The next largest institutional holding, with 2.15 million shares, is of Perceptive Advisors Llc’s that is approximately 6.20% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $7.03 million.
Also, the Mutual Funds coming in first place with the largest holdings of Concert Pharmaceuticals Inc. (CNCE) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Sep 29, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.8 million shares. This amounts to just over 2.30 percent of the company’s overall shares, with a $2.61 million market value. The same data shows that the other fund manager holds slightly less at 0.39 million, or about 1.11% of the stock, which is worth about $1.26 million.